Oligonucleotide Synthesis: Scale-Up Made Simple

By Stefan Hyde, Automation Manager, Asahi Kasei Bioprocess, and Yvonne Duckworth, Fellow, Digital Technology Group Leader, CRB

Oligonucleotide synthesis is a cornerstone of modern nucleic acid-based therapies, offering immense potential to treat diseases like genetic disorders and cancer. However, scaling up the synthesis process presents significant challenges, particularly when moving from benchtop systems to large-scale production. This article delves into the complexities of oligonucleotide scale-up, exploring why it's not a simple copy-and-paste process.

Factors like column dimensions, bed heights, and critical process parameters must be carefully assessed to ensure successful transition to commercial-scale platforms. Learn about solutions like plug-and-play synthesizer systems equipped with intuitive automation software, like Asahi Kasei Bioprocess’s OCELOT™ System Control. Designed to simplify process development and scaling, OCELOT offers customizable templates, remote access, and seamless integration into existing IT infrastructures. Whether you’re expanding within the same manufacturer’s equipment range or transitioning to a different vendor, having the right tools and technical support is critical for success. If you're navigating the challenges of oligonucleotide synthesis scale-up, read the full paper to capture valuable insights into streamlining the process, improving yields, and ultimately accelerating your path to market​